Nitto-denko Corporation

Osaka University

Notto Denko Corporation

Daisuke Asari

Mitsuhiko Hori

Takuya Shishido

Kyohei Matsushita

Katsuyuki Okubo

Arimichi Okazaki

Masahiro Fukasaka

Eiji Kiyotoh

Haruo Sugiyama

Yoshiki Maeda

Wenjing Li

Shizuo Akira

Osamu Takeuchi

Keiko Ogawa

The present invention provides an immunity induction-promoting composition which has a track record of use as a medicine or medicinal additive and is capable of safely and effectively inducing cellular immune response, and a vaccine pharmaceutical composition containing the immunity induction-promoting composition. The present invention relates to an immunity induction-promoting composition containing an immunity induction promoter whose active ingredient is an antimicrobial drug.

Immunity induction promoting composition, and vaccine pharmaceutical composition

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates

The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.

Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration

The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an amino acid.

Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation

The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease. The vaccine composition contains: an immunomodulator which is a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of, and, or a salt of the lipopolysaccharide; and at least one allergen.

Allergy vaccine composition

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of humoral immunity against various antigens and exerting a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity, including: an antigen; and an immunity induction promoter that is a bisphosphonate.

Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity

The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition

The present invention aims to provide a humoral immunity induction-promoting composition and a vaccine pharmaceutical composition which can universally be used for inducing humoral immunity to various antigens and exert a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity containing an antigen and a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.

Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug

The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

WT1 peptide cancer vaccine composition for transdermal administration

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt, derived from at least one gram-negative bacterium such as, and, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500.

Vaccine pharmaceutical composition for transdermal administration

The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of, and, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500. The mucosal vaccine composition is administered in an amount effective to induce humoral immunity in the human or animal.

Mucosal vaccine composition

The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

WT1 peptide cancer vaccine composition for mucosal administration

The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising:

Tape preparation of WT1 peptide cancer vaccine for transdermal administration

The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of, and, or a salt thereof.

Growing community of inventors

Osaka, Japan

Daisuke Asari